Video

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma (LBCL).

After little progress was made in the treatment of diffuse large B-cell lymphoma for about a decade, the previous few years have presented key developments in the space, Ramakrishnan says. Novel biology-based strategies and advancements in cell therapies have given patients with LBCL a second opportunity to receive effective treatment, Ramakrishnan explains.

Although CAR T-cell therapy has shifted the needle in LBCL, more work needs to be done, Ramakrishnan continues. Additional research into CAR T-cell therapy in the future will further assist in understanding the biology of LBCL and how to best sequence therapies for patients, Ramakrishnan concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center